Cargando…

An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study

PURPOSE: To describe intravitreal ranibizumab treatment frequency, clinical monitoring, and visual outcomes (including mean central retinal thickness [CRT] and visual acuity [VA] changes from baseline) in neovascular age-related macular degeneration (nAMD) in real-world settings across three ranibiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Eldem, Bora, Lai, Timothy Y. Y., Ngah, Nor Fariza, Vote, Brendan, Yu, Hyeong Gon, Fabre, Alban, Backer, Arthur, Clunas, Nathan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911274/
https://www.ncbi.nlm.nih.gov/pubmed/29502232
http://dx.doi.org/10.1007/s00417-017-3890-8
_version_ 1783316181362409472
author Eldem, Bora
Lai, Timothy Y. Y.
Ngah, Nor Fariza
Vote, Brendan
Yu, Hyeong Gon
Fabre, Alban
Backer, Arthur
Clunas, Nathan J.
author_facet Eldem, Bora
Lai, Timothy Y. Y.
Ngah, Nor Fariza
Vote, Brendan
Yu, Hyeong Gon
Fabre, Alban
Backer, Arthur
Clunas, Nathan J.
author_sort Eldem, Bora
collection PubMed
description PURPOSE: To describe intravitreal ranibizumab treatment frequency, clinical monitoring, and visual outcomes (including mean central retinal thickness [CRT] and visual acuity [VA] changes from baseline) in neovascular age-related macular degeneration (nAMD) in real-world settings across three ranibizumab reimbursement scenarios in the Middle East, North Africa, and the Asia–Pacific region. METHODS: Non-interventional multicenter historical cohort study of intravitreal ranibizumab use for nAMD in routine clinical practice between April 2010 and April 2013. Eligible patients were diagnosed with nAMD, received at least one intravitreal ranibizumab injection during the study period, and had been observed for a minimum of 1 year (up to 3 years). Reimbursement scenarios were defined as self-paid, partially-reimbursed, and fully-reimbursed. RESULTS: More than three-fourths (n = 2521) of the analysis population was partially-reimbursed for ranibizumab, while 16.4% (n = 532) was fully-reimbursed, and 5.8% was self-paid (n = 188). The average annual ranibizumab injection frequency was 4.1 injections in the partially-reimbursed, 4.7 in the fully-reimbursed and 2.6 in the self-paid populations. The average clinical monitoring frequency was estimated to be 6.7 visits/year, with similar frequencies observed across reimbursement categories. On average, patients experienced VA reduction of −0.7 letters and a decrease in CRT of −44.4 μm. The greatest mean CRT change was observed in the self-paid group, with −92.6 μm. CONCLUSIONS: UNCOVER included a large, heterogeneous ranibizumab-treated nAMD population in real-world settings. Patients in all reimbursement scenarios attained vision stability on average, indicating control of disease activity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00417-017-3890-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5911274
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-59112742018-04-24 An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study Eldem, Bora Lai, Timothy Y. Y. Ngah, Nor Fariza Vote, Brendan Yu, Hyeong Gon Fabre, Alban Backer, Arthur Clunas, Nathan J. Graefes Arch Clin Exp Ophthalmol Low Vision PURPOSE: To describe intravitreal ranibizumab treatment frequency, clinical monitoring, and visual outcomes (including mean central retinal thickness [CRT] and visual acuity [VA] changes from baseline) in neovascular age-related macular degeneration (nAMD) in real-world settings across three ranibizumab reimbursement scenarios in the Middle East, North Africa, and the Asia–Pacific region. METHODS: Non-interventional multicenter historical cohort study of intravitreal ranibizumab use for nAMD in routine clinical practice between April 2010 and April 2013. Eligible patients were diagnosed with nAMD, received at least one intravitreal ranibizumab injection during the study period, and had been observed for a minimum of 1 year (up to 3 years). Reimbursement scenarios were defined as self-paid, partially-reimbursed, and fully-reimbursed. RESULTS: More than three-fourths (n = 2521) of the analysis population was partially-reimbursed for ranibizumab, while 16.4% (n = 532) was fully-reimbursed, and 5.8% was self-paid (n = 188). The average annual ranibizumab injection frequency was 4.1 injections in the partially-reimbursed, 4.7 in the fully-reimbursed and 2.6 in the self-paid populations. The average clinical monitoring frequency was estimated to be 6.7 visits/year, with similar frequencies observed across reimbursement categories. On average, patients experienced VA reduction of −0.7 letters and a decrease in CRT of −44.4 μm. The greatest mean CRT change was observed in the self-paid group, with −92.6 μm. CONCLUSIONS: UNCOVER included a large, heterogeneous ranibizumab-treated nAMD population in real-world settings. Patients in all reimbursement scenarios attained vision stability on average, indicating control of disease activity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00417-017-3890-8) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-03-03 2018 /pmc/articles/PMC5911274/ /pubmed/29502232 http://dx.doi.org/10.1007/s00417-017-3890-8 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Low Vision
Eldem, Bora
Lai, Timothy Y. Y.
Ngah, Nor Fariza
Vote, Brendan
Yu, Hyeong Gon
Fabre, Alban
Backer, Arthur
Clunas, Nathan J.
An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study
title An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study
title_full An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study
title_fullStr An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study
title_full_unstemmed An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study
title_short An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study
title_sort analysis of ranibizumab treatment and visual outcomes in real-world settings: the uncover study
topic Low Vision
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911274/
https://www.ncbi.nlm.nih.gov/pubmed/29502232
http://dx.doi.org/10.1007/s00417-017-3890-8
work_keys_str_mv AT eldembora ananalysisofranibizumabtreatmentandvisualoutcomesinrealworldsettingstheuncoverstudy
AT laitimothyyy ananalysisofranibizumabtreatmentandvisualoutcomesinrealworldsettingstheuncoverstudy
AT ngahnorfariza ananalysisofranibizumabtreatmentandvisualoutcomesinrealworldsettingstheuncoverstudy
AT votebrendan ananalysisofranibizumabtreatmentandvisualoutcomesinrealworldsettingstheuncoverstudy
AT yuhyeonggon ananalysisofranibizumabtreatmentandvisualoutcomesinrealworldsettingstheuncoverstudy
AT fabrealban ananalysisofranibizumabtreatmentandvisualoutcomesinrealworldsettingstheuncoverstudy
AT backerarthur ananalysisofranibizumabtreatmentandvisualoutcomesinrealworldsettingstheuncoverstudy
AT clunasnathanj ananalysisofranibizumabtreatmentandvisualoutcomesinrealworldsettingstheuncoverstudy
AT eldembora analysisofranibizumabtreatmentandvisualoutcomesinrealworldsettingstheuncoverstudy
AT laitimothyyy analysisofranibizumabtreatmentandvisualoutcomesinrealworldsettingstheuncoverstudy
AT ngahnorfariza analysisofranibizumabtreatmentandvisualoutcomesinrealworldsettingstheuncoverstudy
AT votebrendan analysisofranibizumabtreatmentandvisualoutcomesinrealworldsettingstheuncoverstudy
AT yuhyeonggon analysisofranibizumabtreatmentandvisualoutcomesinrealworldsettingstheuncoverstudy
AT fabrealban analysisofranibizumabtreatmentandvisualoutcomesinrealworldsettingstheuncoverstudy
AT backerarthur analysisofranibizumabtreatmentandvisualoutcomesinrealworldsettingstheuncoverstudy
AT clunasnathanj analysisofranibizumabtreatmentandvisualoutcomesinrealworldsettingstheuncoverstudy